Core Points - The company held a shareholders' meeting on November 7, 2025, with all resolutions passed without any objections [4][6] - The meeting was chaired by the chairman Zhengyu Yuan and complied with the relevant laws and company regulations [2][7] - All directors and supervisors were present at the meeting, ensuring full participation [3] Proposal Review - The proposal to abolish the supervisory board and amend the Articles of Association was approved [4] - The proposal to revise certain corporate governance systems was also approved [4] - The proposal to appoint the auditing firm for the fiscal year 2025 was passed [4] - A proposal regarding changes to certain fundraising investment projects was approved [6] - The proposal to purchase liability insurance for directors and senior executives was also approved [6] Voting and Legal Compliance - The voting process was conducted through a combination of on-site and online methods, adhering to the Company Law and the company's Articles of Association [2] - The legal firm Shanghai Fangda Law Firm witnessed the meeting, confirming that all procedures were in compliance with applicable laws and regulations [7]

证券代码：688373 证券简称：盟科药业 公告编号：2025-062 上海盟科药业股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 7 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区爱迪生路 53 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 183 | | --- | --- | | 普通股股东人数 | 183 | | 2、出席会议的股东所持有的表决权数量 | 253,896,175 | | 普通股股东所持有表决权数量 | 253,896,175 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 38.7269 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 38.7269 | （四） ...

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: 86-21-2208-1166 邮政编码：200041 传 真 Fax: 86-21-5298-5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai 200041, PRC 致：上海盟科药业股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海盟科药 业股份有限公司（以下简称"公司"）2025 年第三次临时股东大会（以下简称"本 次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会议人员 的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》及其他相关中华人民共和国境内已公开颁布并生效的法律、 ...

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the supplementary application of the drug "Kangti Zuoan Tablets" and the clinical trial of "MRX-5 Tablets," indicating significant progress in the company's product pipeline and supply chain management [1][4]. Group 1: Kangti Zuoan Tablets - The drug "Kangti Zuoan Tablets" is a new generation oxazolidinone antibiotic developed by the company, approved for treating complex skin and soft tissue infections, and was launched in China in June 2021 [2]. - The recent approval allows Jiangsu Xuantai Pharmaceutical Co., Ltd. to be added as a contracted manufacturing enterprise, and Chongqing Boteng Pharmaceutical Technology Co., Ltd. will supply the active pharmaceutical ingredient [1][3]. - This development is crucial for ensuring stable product supply and meeting market demand, although sales are subject to policy and market environment influences [3]. Group 2: MRX-5 Tablets - "MRX-5 Tablets" is a new type of benzoborazole antibiotic intended for treating infections caused by non-tuberculous mycobacteria (NTM), with an increasing incidence and prevalence of NTM infections [5][6]. - The company has received approval to conduct further clinical trials for a new 200mg specification of MRX-5, which has shown good antibacterial activity and safety in previous trials [4][6]. - MRX-5 has completed Phase I clinical trials in Australia and has been granted orphan drug designation by the US FDA, indicating its potential in the market [6][7].

Group 1 - Triangle Defense signed a gas turbine project development and framework order agreement with Siemens Energy [1] - The development agreement allows Triangle Defense to qualify for supplying specific items to Siemens Energy, detailing technical prerequisites and standards [1] - Triangle Defense specializes in the research, production, and sales of forged products in aviation, aerospace, and shipping industries [1] Group 2 - Aerospace Hongtu was suspended from military procurement for three years due to alleged violations during a procurement activity [2] - The suspension will last from July 6, 2024, to July 6, 2027, affecting the company's participation in military material procurement [2] - Aerospace Hongtu focuses on satellite operations and data collection [3] Group 3 - Kaili Medical's executives purchased a total of 460,000 shares, investing approximately 13.15 million yuan [4] - The average purchase prices were 28.70 yuan and 28.53 yuan per share [4] - Kaili Medical is engaged in the research, production, and sales of medical diagnostic and treatment equipment [5] Group 4 - Muyuan Foods reported a 22.28% year-on-year decline in sales revenue from live pigs in October, totaling 10.33 billion yuan [6] - The average selling price of live pigs decreased by 32.73% year-on-year to 11.55 yuan per kilogram [6] - Muyuan Foods is involved in pig farming and slaughtering [7] Group 5 - Niuwei Co. plans to acquire 40% of its subsidiary Dongwu Machinery for 139 million yuan, aiming for full ownership [8] - Niuwei Co. specializes in the research, manufacturing, and sales of industrial valves [9] Group 6 - Jinlong Automobile reported a 14.71% year-on-year decline in bus sales in October, with 4,121 units sold [10] - Jinlong Automobile focuses on the production and sales of bus products [10] Group 7 - ST Tianshan reported a 242.54% year-on-year increase in sales revenue from live livestock in October, totaling 13.35 million yuan [11] - The company sold 1,367 head of livestock, marking a significant increase compared to previous periods [11] - ST Tianshan is involved in the breeding and sales of cattle and dairy products [12] Group 8 - Ningbo Port expects a 12.4% year-on-year increase in container throughput in October, reaching 4.56 million TEUs [13] - The total cargo throughput is projected to be 99.6 million tons, a 5.3% increase year-on-year [13] - Ningbo Port engages in port handling and logistics services [13] Group 9 - Amcare Pharma received approval for supplementary drug applications and clinical trials for its products [14] - The company is focused on new drug development and utilizes a MAH model for production [14] Group 10 - Lude Environment plans to change its stock name to "Lude Technology" while keeping its full name and stock code unchanged [15] - The company specializes in waste treatment and resource utilization technologies [15] Group 11 - Hualan Co. plans to increase its stake in the company by investing between 30 million and 60 million yuan [16] - The maximum purchase price is set at 58.08 yuan per share [16] - Hualan Co. focuses on the development and sales of packaging materials for injectable drugs [16] Group 12 - Caina Co. is using 140 million yuan of idle funds to purchase structured deposits from a bank, with expected annual yields between 0.70% and 1.85% [17] - Caina Co. specializes in the research, production, and sales of injection and laboratory consumables [17] Group 13 - Zhenghong Technology reported a 52.80% year-on-year decrease in sales revenue from live pigs in October, totaling 4.32 million yuan [18] - The company sold 400 head of pigs, marking a significant decline compared to previous periods [18] - Zhenghong Technology is involved in feed production and pig farming [18] Group 14 - Caida Securities received approval from the CSRC to issue bonds totaling up to 6 billion yuan [19] - The company is engaged in securities brokerage, investment banking, and asset management [19] Group 15 - Jiayuan Technology signed a copper foil supply framework agreement with CATL, establishing a long-term partnership [20] - The agreement includes collaboration in the supply and production of materials for new battery technologies [20] Group 16 - Haikong Group announced the resignation of its general manager due to personal career planning [21] - The company is involved in automotive passenger transport and related services [21] Group 17 - Beizhi Technology's application to acquire 100% of Suzhou Suike Intelligent Technology has been accepted by the Shanghai Stock Exchange [22] - The company specializes in intelligent logistics systems and equipment [22] Group 18 - Yikang Pharma's subsidiary received approval for clinical trials of a new injection for chronic hepatitis B [23] - The company focuses on the production and sales of raw and formulated pharmaceutical products [23] Group 19 - Hengyuan Coal Power plans to acquire 100% of two coal companies for 440 million yuan [24] - The acquisition includes assuming debts totaling 1.137 billion yuan [24] - Hengyuan Coal Power is involved in coal mining and sales [24] Group 20 - Yangpu Medical announced the cancellation of a production arrangement for a medical device [25] - The company specializes in precision medical and testing services [25] Group 21 - Kailong High-Tech plans to establish a 195 million yuan industry fund focusing on unlisted companies [26] - The company is involved in air pollution control and new energy management systems [26] Group 22 - Yingli Co. received approval for its application to acquire a majority stake in a company [27] - The company specializes in precision electronic components and related manufacturing [27] Group 23 - Tianyi Medical's arterial-venous puncture device received EU MDR certification, valid until January 2028 [28] - The company focuses on medical devices for blood purification and care [28] Group 24 - Chuangyuan Co. appointed a new president, effective until the end of the current board term [29] - The company specializes in the design and production of paper products [29] Group 25 - Shanghai Laishi's new indication for a drug received clinical trial approval [30] - The company focuses on the production and sales of blood products [30] Group 26 - Fengmao Co. plans to issue convertible bonds to raise up to 520 million yuan for expansion and working capital [31] - The company specializes in precision rubber components [31] Group 27 - Yinuo Si's shareholder plans to transfer 3% of the company's shares through an inquiry process [32] - The company provides comprehensive R&D services in the biopharmaceutical sector [32] Group 28 - Phoenix Shipping plans to use up to 50 million yuan of idle funds for cash management [33] - The company is involved in dry bulk shipping and logistics services [33] Group 29 - Xingyuan Zhuomei received a notification to supply magnesium alloy components worth 2.021 billion yuan to a new energy vehicle manufacturer [34] - The project is expected to start mass production in the third quarter of 2026 [34] Group 30 - Landai Technology's subsidiary plans to sell electric drive assembly assets for 110 million yuan [35] - The company specializes in power transmission and display technology [35] Group 31 - Yuexiu Capital plans to distribute a cash dividend of 0.90 yuan per share [36] - The company is involved in asset management and private equity [36] Group 32 - Northeast Securities plans to distribute a cash dividend of 1.00 yuan per share, totaling 234 million yuan [37] - The company focuses on wealth management and investment banking [37] Group 33 - Jinguang Electric won a bid for a project from the State Grid worth 21.7976 million yuan [38] - The company specializes in the research and manufacturing of power distribution equipment [39] Group 34 - Huarong Co. plans to repurchase shares worth between 40 million and 125 million yuan [40] - The company focuses on the production and sales of explosion-proof electrical equipment [40] Group 35 - Baiyang Pharma signed a distribution agreement for a blood product, gaining exclusive rights in specific markets [41] - The company specializes in the development and commercialization of medical innovations [41] Group 36 - Li Qun Co.'s director plans to reduce his stake by up to 71,000 shares due to personal financial needs [42] - The company is involved in retail and logistics services [42] Group 37 - Su Li Co.'s shareholder plans to reduce his stake by up to 0.48% of the company's shares [43] - The company specializes in the production and sales of fine chemical products [43] Group 38 - Shenzhen Ruijie obtained a commitment letter for a stock repurchase loan of up to 15.3 million yuan [44] - The company provides project management and evaluation services [44] Group 39 - Fudan Zhangjiang's shareholder plans to reduce his stake by up to 1% of the company's shares [45] - The company focuses on biopharmaceutical research and development [45] Group 40 - Ningbo Zhongbai's shareholder plans to reduce his stake by up to 1% of the company's shares [46] - The company is involved in retail and wholesale operations [46] Group 41 - Jingyi Co. announced a change in control due to a judicial auction of shares [47] - The company specializes in copper processing and digital carbon services [47] Group 42 - Luoping Zinc Electric's subsidiary obtained a new safety production license for mining operations [48] - The company focuses on hydropower and mining activities [48]

Group 1 - Company received approval from the National Medical Products Administration for the supplementary application of the drug "Kangti Zuoan Tablets" and the supplementary application for clinical trials of "MRX-5 Tablets" [1] - "Kangti Zuoan Tablets" is a new generation oxazolidinone antibiotic designed for treating complex skin and soft tissue infections, approved for marketing in China since June 2021 [1] - The approval allows Jiangsu Xuantai Pharmaceutical Co., Ltd. to act as a contract manufacturer, utilizing raw materials from Chongqing Boten Pharmaceutical Technology Co., Ltd., enhancing the product supply chain and ensuring stable supply [1] Group 2 - "MRX-5 Tablets" is a novel benzothiazole antibiotic aimed at treating infections caused by non-tuberculous mycobacteria (NTM), with increasing incidence and prevalence of NTM diseases [1] - The drug shows good antibacterial activity against common NTM, with favorable safety and pharmacokinetic properties demonstrated in animal and human trials [1] - The company has completed Phase I clinical trials in Australia, achieving expected goals, and received orphan drug designation from the US FDA for "MRX-5" [1][2] - The approval of a new 200mg specification for clinical trials will facilitate further clinical research [2]

证券代码：688373 证券简称：盟科药业 公告编号：2025-061 上海盟科药业股份有限公司 自愿披露关于获得药品补充申请及药物临床试验补充申请 批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海盟科药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局出具的《药品补充申请批准通知书》《药物临床试验补充申请批准通知 书》，现将有关情况公告如下： 一、收到《药品补充申请批准通知书》的相关情况 （一）主要内容 药品名称：康替唑胺片 商品名称：优喜泰® （三）对公司的影响及风险提示 本次康替唑胺片获批新增江苏宣泰药业有限公司作为受托生产企业，并将 采用重庆博腾制药科技股份有限公司生产的康替唑胺原料药用于其片剂的商业 化生产，是公司产品供应链布局的重要进展，对保障产品稳定供应、满足市场 需求具有积极意义。但由于药品销售受政策、市场环境等因素的影响，具有较 大不确定性，敬请广大投资者谨慎决策，注意防范投资风险。 二、收到《药物临床试验补充申请批准通知书》的相关情况 （一）主要内容 剂型与规格：片剂 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug "Kangti Zuoan Tablets," marketed as "Youxitai," allowing Jiangsu Xuantai Pharmaceutical Co., Ltd. to act as a contract manufacturer [1] Group 1 - The approval includes the use of raw materials from Chongqing Boten Pharmaceutical Technology Co., Ltd. for the commercial production of Kangti Zuoan Tablets [1] - The company has also initiated additional clinical trials for the MRX-5 Tablets in a new 200mg specification, targeting infections caused by non-tuberculous mycobacteria sensitive to this product [1]

Core Insights - Shanghai Mengke Pharmaceutical Co., Ltd. reported significant operational improvements in its Q3 2025 report, with a notable reduction in losses and continuous revenue growth driven by its core product, Contizolam (brand name: Youxitai®) [1][2] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 104 million yuan, representing a year-on-year increase of 6.58% [1] - The net loss attributable to shareholders narrowed by 33.56% compared to the same period last year [1] - The gross margin for the first three quarters was 84.88%, an increase of 2.65 percentage points year-on-year [1] Product Development - Contizolam, as the first domestically produced oxazolidinone antibiotic, is gaining recognition among doctors and patients due to its effective performance in infection treatment [1] - The company is expanding its market coverage through increased hospital access and bulk procurement, which directly contributes to revenue growth [1] - Strategic optimization and adjustments in the sales model and team have been implemented to enhance sales efficiency and reduce management costs [1] Future Outlook - The company aims to continue its focus on product commercialization and market potential while advancing its research pipeline [2] - Mengke Pharmaceutical is strengthening its core advantages in the anti-infection field and gradually exploring new drug development in oncology and autoimmune diseases [2] - The company is steadily advancing clinical trials in China and globally to provide sustained momentum for long-term development [2]

证券代码：688373 证券简称：盟科药业 公告编号：2025-060 上海盟科药业股份有限公司 关于参加 2025 年上海辖区上市公司三季报集体业绩 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 1 会议召开时间：2025 年 11 月 13 日 （星期四） 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 06 日 （星期四） 至 11 月 12 日 （星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 688373@micurxchina.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 范围内就投资者普遍关注 ...